Centocor Inc. of Malvern, Pa., is talking with a few drugcompanies about a co-promotion plan aimed at boosting salesof its Centoxin drug in Europe, its founder told an investmentconference on Tuesday.
Centocor, whose hopes for U.S. marketing approval of Centoxinwere dealt a setback by the FDA in April, should soon announcea protocol for another round of Phase III clinical trials to meetthe agency's objections, said Michael Wall, who chairs thecompany's executive committee. He spoke to the Paine Webberaggressive growth stock conference in New York.
The co-promotion deal in support of Centoxin in Europe isexpected to produce immediate revenues and would notjeopardize the company's product line by ceding marketingrights, Wall said. The company's shares (NASDAQ:CNTO) weredown 25 cents to $11.63 on Tuesday.
(c) 1997 American Health Consultants. All rights reserved.